Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in Metastatic Colorectal Cancer (FIRST-K)
NCT07510932Phase 2Not yet recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Korea University Anam Hospital. Primary endpoint: Progression-Free Survival up to 24 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07510932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510932.